We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division

Download Mobile App

Siemens Showcases Multiple New IVD Solutions at AACC 2015

By LabMedica International staff writers
Posted on 28 Jul 2015
Print article
Image: Overview of the Siemens Healthcare Diagnostics Booth 1409 at the AACC 2015, showcasing a multidisciplinary portfolio of Siemens’ latest IVD workflow solutions and assays in one location (Image courtesy of Siemens Healthcare).
Image: Overview of the Siemens Healthcare Diagnostics Booth 1409 at the AACC 2015, showcasing a multidisciplinary portfolio of Siemens’ latest IVD workflow solutions and assays in one location (Image courtesy of Siemens Healthcare).
Siemens showcases a multidisciplinary portfolio of its latest in vitro diagnostic (IVD) workflow solutions and assays in one location—Booth 1409 at the 2015 AACC Meeting & Clinical Lab Expo (July 26–30; Atlanta, GA, USA).

Siemens Healthcare Diagnostics division of Siemens Healthcare (Erlangen, Germany) reveals its latest IVD solutions: in addition to featuring its portfolio of multidisciplinary solutions designed for use in hospital, reference, and physician office laboratories and near patients’ bedsides, the booth highlights how Siemens’ customers are achieving their clinical and workflow goals.

“Customers need a reliable partner who can help them achieve higher levels of operational efficiency while providing quality results that lead to optimal patient care,” said Michael Reitermann, CEO, Siemens Healthcare Diagnostics, “The solutions we are showcasing at this year’s AACC can help customers successfully achieve their workflow and clinical goals, regardless of the size of their operations or testing demands.”

One such example, the ADVIA Centaur XPT Immunoassay System1 is a high-throughput analyzer that enhances workflow to meet demands for reliable, rapid immunoassay testing. Recently FDA-cleared, this analyzer is designed to provide simple, continuous operation; accurate, timely results; and powerful, seamless connectivity including to Aptio Automation, the company’s flexible, track-based automation system.

Aptio Automation’s connectivity options include the ADVIA Chemistry XPT System—Siemens’ newest high-throughput chemistry analyzer, and the Sysmex CS-5100 System2 – a high-volume hemostasis analyzer. Siemens is the only single-source provider able to connect all four key laboratory disciplines—chemistry, immunoassay, hematology, and hemostasis—to the automation track.

Also at the booth is the Sysmex CS-2100i System2—a mid-volume benchtop hemostasis analyzer. Both the Sysmex CS-2100i System and Sysmex CS 5100 System utilize simultaneous multi-wavelength detection and first-to-market PSI technology to manage unsuitable coagulation samples (e.g., improperly filled sample tubes) for high-quality results.

Another new hemostasis offering on display—one for point-of-care (POC) testing—is the Xprecia Stride Coagulation Analyzer1. Winner of the Red Dot design award, this handheld system performs prothrombin time testing (PT/INR). In hematology, Siemens now offers to small and mid-sized laboratories the ADVIA 360 Hematology System3 ADVIA 560 Hematology System3 and ADVIA 560 AL Hematology System3 – they provide state-of-the-art testing capabilities and may be used as backup systems for larger labs.

The company’s leadership is also evidenced by its latest products in urinalysis, infectious disease and molecular testing, and customer education.

The CLINITEK AUWi PRO Automated Urinalysis System4 is a walkaway solution for integrated urinalysis testing. It combines a urine chemistry analyzer (CLINITEK Novus Automated Urine Chemistry Analyzer) with a urine sediment analyzer (Sysmex UF-1000i Automated Urine Particle Analyzer).

New infectious disease assays include the ADVIA Centaur HIV Ag/Ab Combo (C-HIV) assay, which allows for sensitive and specific detection of HIV p24 antigen and antibodies and may improve detection of early acute infections. The ADVIA Centaur Syphilis assay is used as a diagnostic aid, allowing for sensitive and specific detection of antibodies to Treponema pallidum in human serum or plasma (EDTA, lithium or sodium heparinized, sodium citrate).

In molecular testing, experts will be on hand to discuss the automated Siemens Tissue Preparation Solution, a reproducible and standardized process for the extraction of high-quality nucleic acid from formalin-fixed paraffin-embedded (FFPE) and fresh frozen (FF) tissues. It is enabling technology for the next generation of molecular diagnostics, including next-generation sequencing (NGS) for infectious disease and oncology testing.

Another innovative offering making its debut at AACC is Siemens PEPconnect, part of the total Personalized Education Plan (PEP)5, the industry’s first personalized learning and performance experience for healthcare professionals and their workgroup communities. With optimized technology and increased search capabilities, PEPconnect enables to access education and real-time performance support almost anytime, anywhere, and on almost any device, including smartphones.

At AACC, Siemens also offers educational workshops on chronic kidney disease and Centers for Disease Control (CDC) recommendations for syphilis and hepatitis C testing.

Related Links:

Siemens Healthcare at AACC 2015
Siemens Healthcare at AACC 2015, featured products
American Association for Clinical Chemistry (AACC)

Gold Supplier
ADAMTS13 Activity Assay
HemosIL ACUSTAR ADAMTS13 Activity Assay
IFA Automated Processor
Silver Supplier
Lipid Profile Analyzer
Cholestech LDX
Silver Supplier
Cartridge Incubator
WS-i60 Cartridge Incubator

Print article



view channel
Image: The CellSearch Circulating Tumor Cell Kit is intended for the enumeration of circulating tumor cells of epithelial origin (CD45-, EpCAM+, and cytokeratins 8, 18+, and/or 19+ and PD-L1) in whole blood (Photo courtesy of CellSearch/Menarini Silicon Biosystems)

PD-L1 Expression in Circulating Tumor Cells Investigated for NSCLC

In non-small cell lung cancer (NSCLC), analysis of programmed cell death ligand 1 (PD-L1) expression in circulating tumor cells (CTCs) is a potential alternative to overcome the problems linked to the... Read more


view channel

Global Digital Polymerase Chain Reaction (dPCR) Market Projected to Reach Close to USD 1.15 Billion by 2028

The global digital polymerase chain reaction (dPCR) market is projected to grow at a CAGR of more than 9% from over USD 0.50 billion in 2020 to nearly USD 1.15 billion by 2028, driven primarily by rising... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.